Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.245,34+0,12 %

Gold2.640,81+0,42 %

Öl (Brent)78,76-0,92 %

Dow Jones42.456,33+0,01 %

US Tech 10020.190,13-0,25 %

EUR/USD1,09334-0,02 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Tempest Therapeutics Aktie

Aktie

ISIN: US87978U1088 WKN: A3CSM8 SYM: 3OS Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,9620

EUR

-3,99 %

-0,0400 EUR

Letzter Kurs 13:12:54 Tradegate

Geldkurs

13:42:53

0,9855

EUR

1.523 STK

Briefkurs

13:42:53

1,0040

EUR

5.980 STK

Tempest Therapeutics Aktie kaufen

Neueste Nachrichten

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial 10.10.24 · globenewswire · Tempest Therapeutics
Tempest Extends Limited Duration Stockholder Rights Plan 10.10.24 · globenewswire · Tempest Therapeutics
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 20.09.24 · globenewswire · Tempest Therapeutics
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs 18.09.24 · globenewswire · Tempest Therapeutics
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference 05.09.24 · globenewswire · Tempest Therapeutics
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 23.08.24 · globenewswire · Tempest Therapeutics
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance 21.08.24 · globenewswire · Tempest Therapeutics
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma 15.08.24 · globenewswire · Tempest Therapeutics
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update 08.08.24 · globenewswire · Tempest Therapeutics
Aktien New York Ausblick: Weitere Tech-Rekorde - Nasdaq 100 mit 20 000 Punkten 20.06.24 · dpa-AFX · Applied Materials
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm 20.06.24 · globenewswire · Tempest Therapeutics
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma 19.06.24 · globenewswire · Tempest Therapeutics

1
2
…
3

Meistgelesen

7 Tage
30 Tage
12 Monate

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into ... 220 Leser
Tempest Extends Limited Duration Stockholder Rights Plan 132 Leser

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, ... 484 Leser
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 324 Leser
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into ... 220 Leser
Tempest Extends Limited Duration Stockholder Rights Plan 132 Leser

Krebsmedikament: Wahnsinns-Rallye: Aktie schießt um 4.000% in die Höhe nach Studien-Erfolg 31364 Leser
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in ... 1940 Leser
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study ... 1864 Leser
Tempest-Aktie +4.000%: Wie geht das denn?! 1180 Leser
Tempest Adopts Limited Duration Stockholder Rights Plan 848 Leser
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat ... 800 Leser
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study ... 636 Leser
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update 560 Leser
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference 536 Leser
Aktien New York Ausblick: Weitere Tech-Rekorde - Nasdaq 100 mit 20 000 Punkten 496 Leser